Radiopharm Theranostics Ltd Market Cap ($15.49 Million)
Market Cap & Net Worth: Radiopharm Theranostics Ltd (RAD)
Radiopharm Theranostics Ltd market cap. Radiopharm Theranostics Ltd (AU:RAD) has a market capitalization of $15.49 Million (AU$21.89 Million) as of November 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25736 globally and #1108 in its home market, demonstrating a 11.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Radiopharm Theranostics Ltd's stock price AU$0.01 by its total outstanding shares 4377549491 (4.38 Billion). Also see cash efficiency ratio of Radiopharm Theranostics Ltd for how efficiently the company converts equity into cash flow.
Radiopharm Theranostics Ltd Market Cap History (2021–2026)
Radiopharm Theranostics Ltd market cap history from 2021 to 2026. Data shows change from $1.12 Billion to $15.49 Million (-58.05% CAGR). Check Radiopharm Theranostics Ltd (RAD) stock price for real-time trading data and today's change.
Radiopharm Theranostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Radiopharm Theranostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Radiopharm Theranostics Ltd annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.60x
Radiopharm Theranostics Ltd's market cap is 5.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $307.26 Million | $8.83K | -$30.34 Million | 34793.52x | N/A |
| 2023 | $229.21 Million | $292.36K | -$34.61 Million | 783.99x | N/A |
| 2024 | $74.34 Million | $299.23K | -$47.95 Million | 248.43x | N/A |
| 2025 | $77.43 Million | $13.40 Million | -$36.70 Million | 5.78x | N/A |
| 2026 | $15.49 Million | $2.77 Million | -$55.15 Million | 5.60x | N/A |
Competitor Companies of RAD by Market Capitalization
Companies near Radiopharm Theranostics Ltd in the global market cap rankings as of November 4, 2026. Also see total assets of Radiopharm Theranostics Ltd for a full breakdown of the balance sheet.
Key companies related to Radiopharm Theranostics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Radiopharm Theranostics Ltd (2021–2026)
Market capitalization of Radiopharm Theranostics Ltd from 2021 to today. Between 2021 and today, Radiopharm Theranostics Ltd's market cap moved from $1.12 Billion to $ 15.49 Million, with a yearly change of -58.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$15.49 Million | -80.00% |
| 2025 | AU$77.43 Million | +4.17% |
| 2024 | AU$74.34 Million | -67.57% |
| 2023 | AU$229.21 Million | -25.40% |
| 2022 | AU$307.26 Million | -72.49% |
| 2021 | AU$1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Radiopharm Theranostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.49 Million USD |
| MoneyControl | $15.49 Million USD |
| MarketWatch | $15.49 Million USD |
| marketcap.company | $15.49 Million USD |
| Reuters | $15.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeuti… Read more